Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
80 studies found for:    chelation AND heart
Show Display Options
Rank Status Study
1 Completed
Has Results
Trial to Assess Chelation Therapy (TACT)
Condition: Coronary Artery Disease
Interventions: Drug: EDTA;   Drug: EDTA Placebo;   Dietary Supplement: High Dose Vitamin;   Dietary Supplement: High Dose Vitamin Placebo
2 Completed Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
Conditions: Iron Overload;   Cardiomyopathy
Interventions: Drug: Deferoxamine and Deferiprone;   Drug: Deferoxamine
3 Recruiting Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
Conditions: Transfusion-dependent β-thalassemia Patients;   Cardiac Iron Overload
Interventions: Drug: Deferasirox;   Drug: Deferasirox + Deferoxamine
4 Recruiting An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Condition: Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplastic Syndromes, Myelofibrosis, Other Anemia
Intervention: Radiation: Single arm MRI test
5 Completed Efficacy Study in Removing Excess Iron From the Heart
Conditions: Thalassemia Major;   Hemosiderosis
Interventions: Drug: Ferriprox (deferiprone);   Drug: Desferal (deferoxamine)
6 Completed
Has Results
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
Conditions: Transfusional Iron Overload;   Transfusional Hemosiderosis
Interventions: Drug: Core Study: Deferasirox;   Drug: Core Study: Deferoxamine;   Drug: Extension: deferoxamine to deferasirox;   Drug: Extension: deferasirox to deferoxamine;   Drug: Deferasirox;   Drug: Deferoxamine
7 Completed Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Conditions: Beta-thalassemia;   Iron Overload
Intervention: Drug: Deferasirox
8 Unknown  Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
Condition: Acute Kidney Injury
Interventions: Drug: deferiprone;   Drug: Placebo
9 Recruiting Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
Condition: Thalassemia Major With Severe Transfusional Iron Overload
Intervention: Drug: Deferasirox and deferiprone
10 Active, not recruiting Cardiac Function in Patients With Hereditary Hemochromatosis
Condition: Hemochromatosis
Intervention:
11 Unknown  Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: deferiprone
12 Recruiting Amlodipine for Myocardial Iron in Thalassemia
Condition: Thalassemia
Interventions: Drug: Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone);   Drug: Amlodipine
13 Unknown  Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Conditions: Anemia, Sickle Cell;   Transfusion Hemochromatosis
Intervention: Drug: deferasirox
14 Completed Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
Condition: ISCHEMIC CARDIOMYOPATHY
Intervention: Drug: 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
15 Recruiting Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Conditions: Hemochromatosis;   Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Other: Venesection
16 Completed Combo Chelation Trial
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
17 Recruiting Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study
Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox;   Drug: Deferasirox placebo
18 Withdrawn Treatment of Iron Overload Requiring Chelation Therapy
Conditions: Transfusional Iron Overload;   Iron Overload;   Iron Chelation;   Beta-thalassemia;   Transfusional Hemosiderosis;   Iron Metabolism Disorders;   Metabolic Diseases
Interventions: Drug: SPD602;   Drug: Deferasirox
19 Active, not recruiting Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
Conditions: Thalassemia;   Sickle Cell Disease;   Myelodysplasia
Intervention: Biological: Blood sample
20 Completed Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
Condition: Contrast-Induced Acute Kidney Injury
Interventions: Drug: CRMD-001-Deferiprone;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years